AIRNA Closes $90 Million Series A to Advance Novel RNA-Editing Therapeutics
Accelerate the advancement of best-in-class drug candidates into clinical trials.
RNA editing biotech AIRNA recently announced an oversubscribed $60 million financing round, bringing its total Series A raise to $90 million. The round was led by Forbion, with participation from new investors Ono Venture Investment and Alexandria Venture Investments, as well as existing shareholders including ARCH Venture Partners and ND Capital. Gaorong Ventures also joined this round.
The proceeds will accelerate AIRNA's lead candidate into clinical development and further expand the company's pipeline.
"A轮融资汇集了一批顶级的投资机构，支持AIRNA通过RNA碱基编辑来实现改善病人生活的愿景。我们致力于明年将首个候选药物推向临床，并推进RNA碱基编辑平台建设，以解锁其他方式无法实现的治疗目标。"
Founded with support from ARCH Venture Partners, AIRNA builds on the pioneering research of academic co-founders Thorsten Stafforst and Jin Billy Li to create a novel class of RNA therapeutics. The company is developing medicines through its RESTORE+™ platform to address a range of unmet medical needs, optimizing oligonucleotide sequence, chemistry, and delivery to enable precise, efficient, and safe RNA editing.
AIRNA's first clinical candidate is a potential best-in-class therapeutic targeting Alpha-1 antitrypsin deficiency (AATD) — a genetic disorder that primarily affects the lungs and liver.
About AIRNA
AIRNA is pioneering RNA editing therapies to transform patients' lives. RNA editing uses drug modalities that are amenable to repeat dosing and straightforward manufacturing to treat diseases that other drug formats cannot address, with the potential to lead the next generation of RNA therapeutics. The company's RESTORE+™ platform is built on the foundational research of academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University) on precision RNA editing.
AIRNA is advancing a best-in-class candidate for AATD, a genetic disease, alongside a pipeline of programs targeting multiple unmet needs.
